Commencement of LPS challenge trial for lead candidate EP395
Regulatory approval for proof of pharmacology study for the first non-antibiotic macrolide REYKJAVIK, ICELAND – 31 August 2022 – EpiEndo...
OUR NEWS & EVENTS
- Jun 15
Dag Nesse appointed as Director of Clinical Operations
REYKJAVIK, ICELAND – 15 June 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company...
- May 18
Successful completion of Phase I Study for lead asset EP395
· First non-antibiotic macrolide to go into clinical development – targeting COPD · Safety, tolerability and pharmacokinetic...
- May 9
Dr Isaac Cohen and Dr Eugen Steiner appointed to EpiEndo’s Board of Directors
REYKJAVIK, ICELAND – 9 May 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), the clinical-stage biopharmaceutical company...
- Apr 21
EpiEndo expands operations with new facility in Sweden’s largest life science cluster
Grows team across Sweden, Denmark, Iceland, and the UK REYKJAVIK, ICELAND – 21 April 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’), the...
- Mar 24
EpiEndo Pharmaceuticals expands its leadership team, appointing Stefan Petursson as CFO
REYKJAVIK, ICELAND – 24 March 2022 – EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief...
- Feb 14
EpiEndo - A Nordic star on a Global mission!
In the January edition of the Nordic Life Science Magazine (www.nordiclifescience.org), the leading life science business magazine in the...
- Jan 10
We are looking for a biology technician at EpiEndo Pharmaceuticals, is that you?
EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as...
- Jan 10
We are looking for a biologist at EpiEndo Pharmaceuticals, is that you?
EpiEndo Pharmaceuticals is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common...
- Dec 13, 2021
We are looking for a Director Clinical Operations at EpiEndo Pharmaceuticals, is that you?
EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many...
- Oct 25, 2021
EpiEndo Pharma wins the Swedish American Life Science Summit (SALSS) Rising Star Award 2021
EpiEndo Pharma receives the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021 for its innovation and potential impact in
- Aug 18, 2021
EpiEndo Secures €20 Million Series A Funding
EpiEndo Pharmaceuticals Secures €20M Series A Funding to Advance Clinical Development of its Lead Compound EP395 for the Treatment of COPD
- Jun 2, 2021
EpiEndo Wins #1 Place in Biotech & Pharmaceuticals, at the European Innovation Council Investor Day
EpiEndo is announced as the winner of the Biotech & Pharmaceuticals category, at the European Innovation Council Investor Day on Health 2021
- Apr 15, 2021
EpiEndo Announces €2.7 million Investment by the European Innovation Council (EIC) Fund
EpiEndo Pharma is the recipient of a €2.7 million convertible loan from the European Innovation Council (EIC) Fund.
- Apr 13, 2021
EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of Lead Candidate EP395
First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines...
- Apr 6, 2021
EpiEndo Pharma announces the Appointment of Sigriður Valgeirsdóttir and Robert Helgason
EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board
- Mar 5, 2021
EpiEndo and AlveoliX Receive Eurostar Grant
EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar...
- Mar 2, 2021
EpiEndo Pharma Builds Science and Medical Leadership with Appointment of New CSO & CMO
EpiEndo Pharma Builds Science and Medical Leadership with Appointment of New CSO & CMO
- Feb 24, 2021
EpiEndo Pharmaceuticals Appoints Maria Bech as New CEO to Support Move into Clinical Development
REYKJAVIK, ICELAND – 24 February 2021 – EpiEndo Pharmaceuticals (www.epiendo.com) The Board of EpiEndo Pharmaceuticals is pleased to...
- Jan 5, 2021
EpiEndo Receives CTA Approval from UK MHRA for First-in-Man Trials of Lead Compound EP395
REYKJAVIK, ICELAND - 5 January 2021 - EpiEndo Pharmaceuticals (www.epiendo.com) announced today that the Company has received approval...